Detalles de la búsqueda
1.
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden.
Diabetes Obes Metab
; 22(9): 1586-1597, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32329136
2.
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Diabetes Obes Metab
; 21(3): 611-621, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362224
3.
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
JHEP Rep
; 4(9): 100525, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36039144
4.
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Pharmacoeconomics
; 40(8): 751-776, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789987
5.
The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment.
Obes Surg
; 32(4): 998-1004, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35083702
6.
The substantial costs to society associated with obesity - a Danish register-based study based on 2002-2018 data.
Expert Rev Pharmacoecon Outcomes Res
; 22(5): 823-833, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35297718
7.
The prevalence of comorbidities in Danish patients with obesity - A Danish register-based study based on data from 2002 to 2018.
Clin Obes
; 12(5): e12542, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768944
8.
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
Endocrinol Diabetes Metab
; 4(3): e00259, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34277983
9.
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Adv Ther
; 37(3): 1248-1259, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048148
10.
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.
Pharmacoeconomics
; 38(9): 953-969, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32399797
11.
Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.
Diabetes Ther
; 11(5): 1061-1075, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32193837
12.
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Adv Ther
; 37(5): 2427-2441, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32306244
13.
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions.
Pharmacoeconomics
; 38(10): 1123-1133, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656686
14.
Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Pharmacoeconomics
; 38(5): 485-497, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31919793
15.
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
J Clin Endocrinol Metab
; 105(12)2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32827435
16.
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Adv Ther
; 36(5): 1200, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30980280
17.
Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India.
Value Health Reg Issues
; 18: 65-73, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30502662
18.
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Adv Ther
; 36(5): 1190-1199, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30875029
19.
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Pharmacoecon Open
; 3(4): 537-550, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30927241
20.
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Diabetes Ther
; 10(4): 1297-1317, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31098942